Cargando…

Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study

We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeleniuch-Jacquotte, A, Shore, R E, Koenig, K L, Akhmedkhanov, A, Afanasyeva, Y, Kato, I, Kim, M Y, Rinaldi, S, Kaaks, R, Toniolo, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395327/
https://www.ncbi.nlm.nih.gov/pubmed/14710223
http://dx.doi.org/10.1038/sj.bjc.6601517
_version_ 1782155481304793088
author Zeleniuch-Jacquotte, A
Shore, R E
Koenig, K L
Akhmedkhanov, A
Afanasyeva, Y
Kato, I
Kim, M Y
Rinaldi, S
Kaaks, R
Toniolo, P
author_facet Zeleniuch-Jacquotte, A
Shore, R E
Koenig, K L
Akhmedkhanov, A
Afanasyeva, Y
Kato, I
Kim, M Y
Rinaldi, S
Kaaks, R
Toniolo, P
author_sort Zeleniuch-Jacquotte, A
collection PubMed
description We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2.49 (1.47–4.21), P(trend)=0.003 for oestradiol; 3.24 (1.87–5.58), P(trend)<0.001 for oestrone; 2.37 (1.39–4.04), P(trend)=0.002 for testosterone; 2.07 (1.28–3.33), P(trend)<0.001 for androstenedione; 1.74 (1.05–2.89), P(trend)<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31–0.82), P(trend)<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92–1.26 for testosterone; 1.15, 95% CI=0.95–1.39 for androstenedione and 1.06, 95% CI=0.90–1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.
format Text
id pubmed-2395327
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23953272009-09-10 Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study Zeleniuch-Jacquotte, A Shore, R E Koenig, K L Akhmedkhanov, A Afanasyeva, Y Kato, I Kim, M Y Rinaldi, S Kaaks, R Toniolo, P Br J Cancer Epidemiology We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2.49 (1.47–4.21), P(trend)=0.003 for oestradiol; 3.24 (1.87–5.58), P(trend)<0.001 for oestrone; 2.37 (1.39–4.04), P(trend)=0.002 for testosterone; 2.07 (1.28–3.33), P(trend)<0.001 for androstenedione; 1.74 (1.05–2.89), P(trend)<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31–0.82), P(trend)<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92–1.26 for testosterone; 1.15, 95% CI=0.95–1.39 for androstenedione and 1.06, 95% CI=0.90–1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production. Nature Publishing Group 2004-01-12 2004-01-06 /pmc/articles/PMC2395327/ /pubmed/14710223 http://dx.doi.org/10.1038/sj.bjc.6601517 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Zeleniuch-Jacquotte, A
Shore, R E
Koenig, K L
Akhmedkhanov, A
Afanasyeva, Y
Kato, I
Kim, M Y
Rinaldi, S
Kaaks, R
Toniolo, P
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title_full Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title_fullStr Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title_full_unstemmed Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title_short Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
title_sort postmenopausal levels of oestrogen, androgen, and shbg and breast cancer: long-term results of a prospective study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395327/
https://www.ncbi.nlm.nih.gov/pubmed/14710223
http://dx.doi.org/10.1038/sj.bjc.6601517
work_keys_str_mv AT zeleniuchjacquottea postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT shorere postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT koenigkl postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT akhmedkhanova postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT afanasyevay postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT katoi postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT kimmy postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT rinaldis postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT kaaksr postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy
AT toniolop postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy